Viking Therapeutics (0VQA) Financial Statements
Viking Therapeutics Financial Overview
Viking Therapeutics's market cap is currently $3.48B. The company's EPS TTM is $-5.40; its P/E ratio is -5.05; Viking Therapeutics is estimated to report earnings on February 10, 2027, and the estimated EPS forecast is $-1.38. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -431.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -393.34M | $ -150.92M | $ -100.83M | $ -70.36M | $ -55.68M |
| EBITDA | $ -359.15M | $ -109.52M | $ -85.52M | $ -68.52M | $ -54.68M |
| Net Income | $ -359.64M | $ -109.96M | $ -85.89M | $ -68.87M | $ -54.99M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 705.74M | $ 902.61M | $ 362.08M | $ 155.49M | $ 202.10M |
| Total Assets | $ 715.73M | $ 908.32M | $ 368.49M | $ 168.53M | $ 210.66M |
| Total Debt | $ 137.00K | $ 1.12M | $ 1.26M | $ 1.56M | $ 29.00K |
| Net Debt | $ -165.67M | $ -25.56M | $ -54.26M | $ -35.07M | $ -26.34M |
| Total Liabilities | $ 76.67M | $ 28.04M | $ 20.07M | $ 23.21M | $ 8.78M |
| Stockholders' Equity | $ 639.06M | $ 880.28M | $ 348.42M | $ 145.32M | $ 201.88M |
| Cash Flow | |||||
| Free Cash Flow | $ -278.69M | $ -87.79M | $ -73.38M | $ -48.40M | $ -47.59M |
| Operating Cash Flow | $ -278.69M | $ -87.79M | $ -73.38M | $ -48.40M | $ -47.59M |
| Investing Cash Flow | $ 341.39M | $ -553.37M | $ -179.09M | $ 54.75M | $ 37.96M |
| Financing Cash Flow | $ 76.44M | $ 612.46M | $ 271.38M | $ 4.16M | $ 6.88M |
Currency in USD